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ABSTRACT
Objective: To assess the relationship between serum
tryptase and the occurrence of major cardiovascular
and cerebrovascular events (MACCE) at 2-year follow-
up in patients admitted with acute coronary syndrome
(ACS). To compare serum tryptase to other validated
prognostic markers (maximum high-sensitivity
troponin (hs-Tn), C reactive protein (CRP) levels at
admission, Synergy between percutaneous coronary
intervention with Taxus and Cardiac Surgery (SYNTAX)
score).
Methods: We measured serum tryptase at admission
in 140 consecutive patients with ACS and in 50 healthy
controls. The patients’ follow-up was maintained for
2 years after discharge. The predictive accuracy of
serum tryptase for 2-year MACCE was assessed and
compared with hs-Tn, CRP and SYNTAX score.
Results: Serum tryptase levels at admission were
significantly higher in patients with ACS compared with
the control group (p=0.0351). 2 years after discharge,
28/140 patients (20%) experienced MACCE. Serum
tryptase levels, maximum hs-Tn measurements and
SYNTAX score were higher in patients who experienced
MACCE compared with those without (p<0.0001).
Conversely, we found no significant association
between MACCE and CRP. The predictive accuracy of
serum tryptase for MACCE was set at the cut-off point
of 6.7 ng/mL (sensitivity 46%, specificity 84%).
Conclusions: In patients with ACS, serum tryptase
measured during index admission is significantly
correlated to the development of MACCE up to 2 years,
demonstrating a possible long-term prognostic role of
this biomarker.
INTRODUCTION
Although atherosclerosis is currently consid-
ered a multifactorial disease, data linking the
pathogenesis of acute coronary syndromes
(ACS) to systemic markers of inﬂammation
have burgeoned in the past decades.1–4
Inﬂammation is an important triggering
event leading to atherothrombotic clinical
manifestations and may exert a pivotal role
on long-term risk stratiﬁcation.3 Many types
of inﬂammation markers are able to guide
leucocytes and platelet adhesion and have
been shown to be predictive of death and
myocardial infarction (MI) in patients with
coronary artery disease.5 Several studies have
documented the high sensitivity and speciﬁ-
city of acute phase response indicators, such
as C reactive protein (CRP), interleukin-1
receptor antagonist (IL-1Ra) and IL-6, evalu-
ated on admission, in predicting the recur-
rence of adverse events during both
hospitalisation and follow-up.6 7
Furthermore, histological analyses of athero-
sclerotic plaques have revealed an acute
inﬂammatory cell inﬁltrate at the site of
plaque rupture1 8 and documented its
KEY QUESTIONS
What is already known about this subject?
▸ Inflammation exerts a pivotal role in the coron-
ary artery plaque instabilisation. Among different
mediators, mast cells and their neutral proteases
have gained interest because of their proathero-
genic role. Our group’s preliminary experiences
have suggested a prognostic role of serum tryp-
tase measured at admission in patients with
acute coronary syndrome (ACS).
What does this study add?
▸ This study confirms the role of serum tryptase
for stratification and prognostication in patients
with ACS in a larger population sample. A
cut-off point of 6.7 ng/mL measured at admis-
sion could have the best predictive accuracy for
2-year follow-up cardiovascular events.
How might this impact on clinical practice?
▸ Serum tryptase measured at admission in patients
with suspected ACS, negative troponin and not
diagnostic ECG could help to early rule out.
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involvement in localised destabilisation processes of
ﬁbrous cap tissues,1 therefore enhancing the risk of cor-
onary thrombosis. These ﬁndings raise the chance of
both improving patients’ risk stratiﬁcation and assessing
the response to new and more speciﬁc treatments.
Accordingly, a renewed interest for the shoulder regions
of atheromas and its dynamic changes during athero-
thrombotic events has been provided. This is an intimal
area characterised by high circumferential stress.9 10
Pathological studies of coronary arteries of patients suf-
fering MI have demonstrated that atheromas typically
rupture in this region. Previous studies have revealed
that this area is heavily populated with activated macro-
phages which may synthesise and secrete several pro-
teases capable of degrading various components of the
extracellular matrix. Moreover, this region is also popu-
lated by mast cells. Mast cells originate from precursors
that arise in the bone marrow. They are released in the
bloodstream and migrate to speciﬁc tissue sites, where
they differentiate locally into mast cells under the inﬂu-
ence of cytokines.11 Depending on the stimuli within
the surrounding milieu, mast cells release numerous
products with the ability to modulate a wide range of
biological activities ranging from inﬂammation to vascu-
lar permeability. These cells have a 10-fold higher
amount of neutral proteases compared with poly-
morphonuclear leucocytes and, through them, they may
activate the metalloproteinases synthesised by the macro-
phages present in human atherosclerotic plaques and
participate in the development of macrophage foam
cells.12 13 Furthermore, mast cells release cytokines that
may induce angiogenesis and vascular apoptosis.14 All
evidences point towards the proatherogenic role of mast
cells and their neutral proteases, chymase and tryptase,
affecting atherosclerosis lesion formation, progression
and destabilisation.15 16
Previous experiments have shown that mast cells con-
centration in the shoulder region of atheromas is
50-fold higher than in normal intima. These mast cells
mostly contain tryptase, whereas the presence of the
other neutral protease, chymase, is highly variable.15
It follows that mast cell-mediated mechanisms may
have a leading role in ACS and their protease tryptase
might be considered a target for diagnostic, prognostic
and therapeutic purposes in this setting. However, previ-
ous studies exploring the role of serum tryptase in the
clinical setting of ACS have reported conﬂicting
results.17–21 Furthermore, none of them have speciﬁcally
addressed the comparison between the levels of tryptase
and those of the other markers considered as the refer-
ence standards for diagnostic and prognostic classiﬁca-
tion of ACS. Finally, none of them have linked tryptase
levels to the extension and severity of coronary artery
disease, evaluated according to accurate and validated
tools. In a previous pilot study performed by our group,
serum tryptase has shown a good performance both as a
diagnostic and prognostic tool and has been correlated
with the extension and severity of coronary artery
disease as deﬁned by the SYNTAX (Synergy between
percutaneous coronary intervention with Taxus and
Cardiac Surgery) score.22 23
The aim of our paper was to prospectively study a con-
secutive and wider sample of patients with ACS, to
measure serum tryptase levels during hospitalisation, to
evaluate its performance as a diagnostic and prognostic
tool in comparison to maximum troponin measure-
ments and to correlate it with the extension and severity
of coronary artery disease as deﬁned by the SYNTAX
score.
METHODS
Patients selection
We prospectively enrolled 140 consecutive patients with
ACS admitted to the cardiovascular department of the
‘ASST Grande Ospedale Metropolitano Niguarda’
(Milan, Italy) from January 2013 to December 2014.
Furthermore, we included in the study 50 participants
without heart diseases and allergic disorders at the time
of recruitment, enrolled as volunteers in our hospital,
who were considered as the healthy control group.
Exclusion criteria included a history of concomitant auto-
immunity diseases, severe allergies, cancer, renal failure,
mastocytosis, refractory anaemias, myelodysplastic syn-
dromes, hypereosinophilic syndrome and patients receiv-
ing recombinant human stem cell. For the purpose of
this study, patients were divided according to the ACS
type (ST-elevation ACS (STEACS) and non-ST-elevation
ACS (NSTEACS)).
Traditional cardiovascular risk factors, such as diabetes
mellitus, hypertension and dyslipidaemia, were deﬁned
when patients were known to have the given risk factors
prior to the index admission and were already on treat-
ment. MI was deﬁned in accordance with the universal
deﬁnition proposed in 2012.24 Chronic obstructive pul-
monary disease (COPD) was deﬁned based on the pres-
ence of chronic airﬂow limitation, as assessed by
postbronchodilator spirometry.
The Institutional Review Board approved the protocol,
and all patients signed a written informed consent form.
The study was carried out in accordance with the Code
of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments involving humans.
Procedures
All study patients underwent invasive coronary arteriog-
raphy and SYNTAX score was computed using the
SYNTAX score algorithm, which is described in detail
elsewhere25 26 and is available on the SYNTAX score
website.27 For patients with STEACS, SYNTAX score was
calculated using the angiographic views of the
infarct-related artery before any intervention.28 Blood for
the evaluation of serum tryptase levels was sampled at
admission (acute phase). The serum was stored at −80°C
before ﬁnal evaluation. Blood samples were also taken in
the same time window from participants in the control
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group. Total tryptase levels were determined by using an
ImmunoCAPtryptase in vitro ﬂuoro-enzyme-immunoassay
test (Phadia, now Thermo Fisher Scientiﬁc, Uppsala,
Sweden), according to the manufacturer’s instructions.
This laboratory method measures the total tryptase levels
of all proforms of α-tryptase and β-tryptase as well as
mature β-tryptase. A normal tryptase level is considered
<5 ng/mL. Furthermore, maximum high-sensitivity
troponin (hs-Tn) and CRP measurements obtained at
admission were also taken into account for statistical ana-
lysis. Hs-Tn quantitative measurements were performed
using an immunoassay test in electrochemiluminescence
(ROCHE Diagnostics GmbH, Mannheim, Germany)
according to the manufacturer’s instructions. The 99th
centile of a healthy reference population is 14 ng/L. CRP
measurement was performed at admission using the
particle-enhanced turbid-metric immunoassay test
(ROCHE Diagnostics GmbH, Mannheim, Germany)
according to the manufacturer’s instructions. The refer-
ence cut-off used to rule out pathological ﬁndings is con-
sidered below 0.5 mg/dL.
Outcome definition
Follow-up of patients lasted 2 years. Outcomes include
major adverse cardiovascular and cerebrovascular events
(MACCE) deﬁned as the composite of overall mortality,
recurrent MI and stroke.
Statistical analysis
All data were analysed with the usual descriptive techni-
ques: categorical data were given as frequency tables,
whereas continuous data were given as mean±SD or as
median and range, according to their distribution,
checked by visual inspection and, when needed, also by
the Shapiro-Wilk test.
Statistical signiﬁcance for categorical variables was
determined with Fisher’s exact test, while that of con-
tinuous variables was calculated with either the
Mann-Whitney U test or Student’s t-test (comparison
among ACS type), one-way analysis of variance between
groups or Kruskal-Wallis test (comparison among
patients with MACCE, without MACCE and healthy con-
trols), followed by post hoc tests according to Sheffé or
Conover. Logistic regression was used to search for statis-
tical signiﬁcance of continuous and categorical inde-
pendent variables with respect to a dependent
dichotomous one: the whole model was checked with
the likelihood ratio test, while any single regressor was
checked with Wald’s test.
Receiver operating characteristic (ROC) analysis was
performed to search for any possible optimal cut-point
by means of the usual Youden’s J statistics. Sensitivity,
speciﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) were calculated for each of these
cut-off values.
All statistical analyses were conducted with Stata/SE
V.14.1 (StataCorp LP, College Station, Texas, USA).
RESULTS
Patients
One hundred and fourteen patients among the total
population were admitted with a diagnosis of ACS: 62
STEACS and 78 NSTEACS. Baseline characteristics of
the enrolled population, as well as pharmacological
treatment during hospitalisation, stratiﬁed according to
the ACS type, are detailed in table 1, whereas angio-
graphic and procedural characteristics are described in
table 2.
Two years after discharge, 28 patients (20%) had
experienced MACCE, 25 patients had recurrent MI
(17.8%), 2 patients died (1.4%) and 1 patient (0.7%)
died after experiencing a recurrent MI. None of the
patients included experienced stroke during the
follow-up period.
Relationships between different clinical and biochemical
parameters
Tryptase/MACCE
Tryptase levels at admission were signiﬁcantly different
in the three groups (patients with MACCE, patients
without MACCE and healthy controls; p<0.0001).
Pairwise comparisons showed higher tryptase levels in
patients experiencing MACCE during the follow-up,
compared both to patients without MACCE (6.86±2.68
vs 5.19±2.65; p=0.004) and healthy controls (3.38±0.94;
p<0.001); patients without MACCE had signiﬁcantly
higher tryptase levels at admission compared with
healthy controls (p<0.001; ﬁgure 1).
Univariate regression analysis showed that a unit
increase in tryptase levels was associated with a 22%
increase in the odds of experiencing an event (Wald’s
test p=0.007).
We searched for a possible cut-off value for tryptase
levels as a predictor of MACCE. The optimal cut-off was
set at 6.7 ng/mL, with 42% PPV (95% CI 25% to 61%),
86% NPV (95% CI 78% to 92%), 46% sensitivity (95%
CI 28% to 66%) and 84% speciﬁcity (95% CI 75% to
90%; ﬁgure 2A). Tryptase ≥6.7 ng/mL was associated
with a 343% increase in the odds of MACCE develop-
ment with an OR of 4.43 (p=0.0007).
Tryptase/other variables
We evaluated the possible association between tryptase
levels and other risk factors for coronary artery disease
as well as known prognostic markers among patients
with ACS. Tryptase levels showed positive associations
with dyslipidaemia (p=0.002), COPD (p=0.025), dia-
betes (p=0.021) and previous MI (p=0.0001) but not
with age (p=0.178), systolic hypertension (p=0.200) and
current smoking habits (p=0.1434). No signiﬁcant corre-
lations between tryptase and hs-Tn p values (p>0.999),
as well as between tryptase and SX-score (p>0.999) or
CRP values (p=0.317), were found.
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Maximum hs-Tn/MACCE
The optimal cut-off for maximum hs-Tn value as a prog-
nostic tool for MACCE was 8890 ng/L, with 86% PPV
(95% CI 42% to 100%), 84% NPV (95% CI 76% to 89%),
21% sensitivity (95% CI 8% to 41%) and 99% speciﬁcity
(95% CI 95% to 100%; Figure 2B). Patients with maximum
hs-Tn level ≥8890 ng/L showed a 2927% increase in the
odds of MACCE with an OR of 30.272 (p<0.00001).
SYNTAX score/MACCE
Univariate analysis showed that any increase in SYNTAX
score was associated with a 10% increase in the risk of
MACCE. The optimal cut-off value for SYNTAX score in
order to predict MACCE was 22 with 52% PPV (95% CI
32% to 72%), 89% NPV (95% CI 80% to 94%), 56%
sensitivity (95% CI 35% to 76%) and 87% speciﬁcity
(95% CI 78% to 93%; ﬁgure 2C). SYNTAX score ≥22
was associated with a 730% increase in the odds of
MACCE with an OR of 8.32 (p<0.00001).
CRP/MACCE
The curve and the corresponding area under curve
showed that CRP does not have a predictive ability in
discriminating patients with MACCE from patients
without events (ﬁgure 2D).
Multivariable analysis
According to multivariable analysis, tryptase levels at
admission remain an independent predictor of MACCE:
OR 1.242413 (95% CI 1.021336 to 1.51344; p=0.03).
Other independent predictors were hs-Tn ((100 units
increase): OR 1.0207 (95% CI 1.0061 to 1.0353,
p=0.005)) and SYNTAX score (OR 1.087078 (95% CI
1.034984 to 1.141793, p=0.001)). The explained variabil-
ity of the model was 32%.
DISCUSSION
The major ﬁndings of the present study are the follow-
ing: (1) tryptase values measured at admission may be a
useful early diagnostic and prognostic tool in patients
with suspected ACS; (2) in patients with conﬁrmed ACS,
tryptase measurement might further improve risk stratiﬁ-
cation when added to a conventional and well-known
validated biomarker such as hs-Tn and angiographic
score system such as SYNTAX-score; (3) a tryptase value
Table 1 Baseline characteristics stratified according to admission diagnosis
Number of patients (%)
Characteristics STEACS (n=62) NSTEACS (n=78) p Value
Age, years 62.0±11.8 65.7±11.2 0.403 (+)
Sex, M/F 47/15 61/17 0.840 (*)
Current smoker 31 (50%) 48 (61.5%) 0.230 (*)
Medical history
Systolic hypertension 41 (66%) 64 (82%) 0.049 (*)
Dyslipidaemia 27 (43%) 45 (58%) 0.126 (*)
Diabetes 12 (19%) 24 (31%) 0.173 (*)
Previous myocardial infarction 9 (14%) 33 (42%) <0.0001 (*)
COPD 10 (16%) 24 (31%) 0.050 (*)
Medications at admission
Aspirin 61 (98%) 77 (99%) >0.999 (*)
Clopidogrel 17 (27%) 35 (45%) 0.052 (*)
Prasugrel 31 (50%) 11 (14%) <0.001 (*)
Ticagrelor 5 (8%) 23 (29%) 0.002 (*)
Oral anticoagulant therapy 3 (5%) 12 (15%) 0.057 (*)
β-Blockers 54 (87%) 61 (78%) 0.121 (*)
Renin–angiotensin system 53 (88%) 61 (78%) 0.266 (*)
Blockers
Diagnostic findings
Tryptase, ng/mL 4.68 (1.17–14.5) 5.2 (1.06–16.3) 0.192 (+)
CRP, mg/dL 0.3 (0–48) 0.3 (0–2.9) 0.808 (+)
Troponin HS, ng/L 2025 (9–19 685) 363 (6–10 713) <0.0001 (+)
Serum triglycerides, mg/dL 107 (45–311) 118 (50–345) 0.109 (+)
HDL cholesterol, mg/dL 42 (18–84) 41 (19–81) 0.864 (+)
LDL cholesterol, mg/dL 106.4 (±29.8) 111.5 (±33.6) 0.372 (++)
Plasma glucose, mg/dL 133 (78–295) 112 (60–403) 0.011 (+)
Left ventricle ejection fraction during index hospitalisation
Ejection fraction 48 (25–60) 48 (30–64) 0.837 (++)
Values are n (%) or median and range or mean+SD depending on the distribution. Comparison performed by Mann-Whitney U test (+),
Student’s t-test (++) and Fisher’s exact (*) tests.
COPD, chronic obstructive pulmonary disease; CRP, serum C reactive protein; F, female; HDL, high-density lipoprotein; HS, high-sensitive;
LDL, low-density lipoprotein; M, male; NSTEACS, non-ST-elevation acute coronary syndrome; STEACS, ST-elevation acute coronary
syndrome.
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>6.7 ng/mL is the optimal cut-off associated with the
worst long-term outcome; therefore, it might be a safe,
cost-effective and efﬁcient method of instant risk stratiﬁ-
cation at admission in this setting; (4) generic markers
of inﬂammation, such as CRP, are not associated with
the follow-up outcome.
The early diagnostic ability of hs-Tn as well as its prog-
nostic value concerning mortality and myocardial rein-
farctions in patients with unstable coronary artery
disease is well validated.29 30 However, clinicians are
often unsure about the prognostic clinical relevance of
slight increases of hs-Tn, especially in patients with
other ongoing disease processes, and are inclined to
ascribe them to patients’ comorbidities. Therefore, an
early and accurate diagnosis and risk stratiﬁcation of
patients with acute chest pain admitted to the emer-
gency room remains a clinical challenge. Inﬂammation
has a leading role in the atherosclerotic process and
may be an early marker of plaque instability. Among
patients with atherosclerotic diseases, mast cells have
been shown to be involved in vascular inﬂammation/
remodelling. Throughout the release of their products,
these cells may affect all the steps of the atherosclerotic
process.31 On activation by different mechanisms, mostly
driven by the main receptor for oxidised low-density
lipoprotein (ox-LDL) on the cell surface, the Toll-like
receptor 4, mast cells release histamine that increases
endothelial permeability to LDL and high-density lipo-
protein (HDL).32 They also release different mediators
that determine proteolysis of HDL. This causes their
inactivation and, as a consequence, the loss of their
useful promotional activity on cholesterol efﬂux from
macrophage foam cells.33 Moreover, since ox-LDL acti-
vates both mast cells and macrophages, these cells syner-
gistically further increase endothelial permeability
through the release of TNF-α, and aggravate the inﬂam-
matory process due to the adhesion and passage of
more inﬂammatory cells.34 The increasing concentration
of activated mast cells leads to a further massive release
of tryptase and chymase that can degrade collagen of
extracellular matrices and many proteins of the ﬁbrous
cap of the atherosclerotic plaques, promoting plaque
destabilisation and its consequential rupture. The wide
vessel remodelling associated with mast cells and their
mediators may explain the worst prognosis of patients
presenting with ACS and higher tryptase levels. The
observation that a high tryptase level identiﬁed the
patients presenting with MACCE after 2 years from ACS
is an in vivo demonstration of tryptase major role as a
marker of the inﬂammatory and atherosclerotic process.
An optimal cut-off level of 6.7 ng/mL for tryptase mea-
surements may identify patients with a higher risk of vas-
cular events and differentiate them from other aspeciﬁc
inﬂammatory processes. Moreover, the signiﬁcant associ-
ation between a positive history of dyslipidaemic altera-
tions and higher tryptase levels could further support
the relationship between mast cell activation and
atherosclerosis.
Finally, it is important to point out how the role of
serum tryptase remains relevant even after adjust-
ment for well-known markers of cardiovascular events
in the ACS setting. It is well known that a gradient of
risk for future cardiovascular events starts at hs-Tn
concentrations close to the limit of detection.35
Interestingly, tryptase values measured at admission
remained an independent predictor of events even
adjusting for this validated and extremely sensible
biomarker, taken at its maximum concentration
during index admission.
Table 2 Angiographic and procedural characteristics
stratified according to admission diagnosis
Number of patients
(%)
Characteristics
STEACS
(n=62)
NSTEACS
(n=78) p Value
Angiographic characteristics
1-Vessel disease 30 (48%) 25 (32%) <0.057 (*)
2-Vessel disease 14 (22%) 18 (23%) >0.999 (*)
3-Vessel disease 12 (19%) 31 (40%) 0.010 (*)
SYNTAX score 12 (0–70) 12 (0–60) 0.589 (+)
Procedural characteristics
Coronary bypass
surgery
3 (5%) 14 (18%) 0.020 (*)
PCI 58 (93%) 71 (91%) 0.755 (*)
Stent type
BMS 7 (11.3%) 8 (10.2%) >0.999 (*)
DES 50 (80.6%) 58 (74.3%) 0.423 (*)
Values are n (%) or median and range or mean+SD depending on
the distribution. Comparison performed by Mann-Whitney U test
(+) and Fisher’s exact (*) tests.
BMS, bare metal stents; DES, drug-eluting stents; NSTEACS,
non-ST-elevation acute coronary syndrome; PCI, percutaneous
coronary intervention; STEACS, ST-elevation acute coronary
syndrome; SYNTAX, Synergy between PCI with Taxus and
Cardiac Surgery.
Figure 1 Box plots show Sheffé-adjusted pairwise
comparisons between patients with MACCE, patients without
MACCE and healthy controls. MACCE, major adverse
cardiovascular and cerebrovascular events.
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This holds true even considering the severity and exten-
sion of coronary artery disease, as evaluated by the
SX-score. SX-score allows an assessment of overall coronary
lesion complexity, with lower scores representing less
complex coronary disease (a low score is deﬁned as <22).36
Not surprisingly, 22 was even the optimal cut-off associated
with the worst long-term outcome in the present analysis.
CONCLUSIONS
In conclusion, serum tryptase might be a further tool to
early identify patients with high risk of ACS and long-
term recurrent events. Its evaluation does not substitute
well validated markers and scores, but might have an
incremental value in more complex settings.
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